The current advances of lncRNAs in breast cancer immunobiology research

Frontiers in Immunology

Immunology

Karla Itzel Vázquez-Santillán¹  Alfredo Hidalgo-Miranda²  Marco Antonio Fonseca-Montaño³ 

[1] Laboratorio de Epigenética, Instituto Nacional de Medicina Genómica (INMEGEN), Mexico City, Mexico;Laboratorio de Genómica del Cáncer, Instituto Nacional de Medicina Genómica (INMEGEN), Mexico City, Mexico;Laboratorio de Genómica del Cáncer, Instituto Nacional de Medicina Genómica (INMEGEN), Mexico City, Mexico;Programa de Doctorado, Posgrado en Ciencias Biológicas, Unidad de Posgrado, Universidad Nacional Autónoma de México (UNAM), Mexico City, Mexico;

关键词: breast cancer;    immune cells;    tumor immune microenvironment;    lncRNAs;    immune response;    biomarker;    prognosis;   

DOI  :  10.3389/fimmu.2023.1194300

 received in 2023-03-26, accepted in 2023-05-24,  发布年份 2023

来源: Frontiers

【 摘 要 】

Breast cancer is the most frequently diagnosed malignancy and the leading cause of cancer-related death in women worldwide. Breast cancer development and progression are mainly associated with tumor-intrinsic alterations in diverse genes and signaling pathways and with tumor-extrinsic dysregulations linked to the tumor immune microenvironment. Significantly, abnormal expression of lncRNAs affects the tumor immune microenvironment characteristics and modulates the behavior of different cancer types, including breast cancer. In this review, we provide the current advances about the role of lncRNAs as tumor-intrinsic and tumor-extrinsic modulators of the antitumoral immune response and the immune microenvironment in breast cancer, as well as lncRNAs which are potential biomarkers of tumor immune microenvironment and clinicopathological characteristics in patients, suggesting that lncRNAs are potential targets for immunotherapy in breast cancer.

【 授权许可】

Unknown   
Copyright © 2023 Fonseca-Montaño, Vázquez-Santillán and Hidalgo-Miranda